Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood marker may predict deadly Post-Surgery complications

NCT ID NCT07144917

First seen Apr 16, 2026 · Last updated May 01, 2026 · Updated 2 times

Summary

This study looks at whether a blood marker called mHLA-DR can help doctors predict severe complications after pancreatic surgery for cancer. About 100 patients will have their immune response measured in the days after surgery. The goal is to find an early warning sign for dangerous issues like pancreatic leaks or infections, which could lead to better care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC FISTULA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Aurélien DUPRE

    NOT_YET_RECRUITING

    Lyon, 69008, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Jean-Christophe LIFANTE

    NOT_YET_RECRUITING

    Pierre-Bénite, 69495, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Julie PERINEL

    NOT_YET_RECRUITING

    Lyon, 69003, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Xavier MULLER

    RECRUITING

    Lyon, 69004, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.